MX2017010763A - Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. - Google Patents
Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.Info
- Publication number
- MX2017010763A MX2017010763A MX2017010763A MX2017010763A MX2017010763A MX 2017010763 A MX2017010763 A MX 2017010763A MX 2017010763 A MX2017010763 A MX 2017010763A MX 2017010763 A MX2017010763 A MX 2017010763A MX 2017010763 A MX2017010763 A MX 2017010763A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- tfpi
- hemophilia
- present
- composition
- Prior art date
Links
- 101150070659 tfpI gene Proteins 0.000 title 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 4
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 4
- 208000009292 Hemophilia A Diseases 0.000 abstract 3
- 208000031220 Hemophilia Diseases 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 230000006624 extrinsic pathway Effects 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un anticuerpo que se une específicamente a un inhibidor de la vía del factor tisular (TFPI), un ácido nucleico que codifica el anticuerpo, un vector que comprende el ácido nucleico, una célula hospedadora transformada con el vector, un método para producir el anticuerpo y una composición farmacéutica para tratar la hemofilia, que comprende el anticuerpo como ingrediente activo. El anticuerpo de la presente invención, que se une específicamente a TFPI, puede activar la ruta extrínseca de la coagulación de la sangre mediante la inhibición de TFPI. De este modo, el anticuerpo de la presente invención se puede usar eficazmente para el tratamiento de pacientes con hemofilia inducida por anticuerpos y para la prevención de la enfermedad de la coagulación sanguínea en pacientes con hemofilia A o hemofilia B.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150026555A KR101744899B1 (ko) | 2015-02-25 | 2015-02-25 | 신규 항-tfpi 항체 및 이를 포함하는 조성물 |
| KR1020150135761A KR101804988B1 (ko) | 2015-09-24 | 2015-09-24 | 신규 항-tfpi 항체 및 이를 포함하는 조성물 |
| PCT/KR2015/014370 WO2016137108A1 (en) | 2015-02-25 | 2015-12-29 | Novel antibody binding to tfpi and composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010763A true MX2017010763A (es) | 2018-06-15 |
| MX388251B MX388251B (es) | 2025-03-19 |
Family
ID=56788831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010763A MX388251B (es) | 2015-02-25 | 2015-12-29 | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10266607B2 (es) |
| EP (2) | EP3262075B1 (es) |
| JP (1) | JP6660957B2 (es) |
| CN (2) | CN112225812B (es) |
| AU (2) | AU2015384281B2 (es) |
| BR (1) | BR112017018328A2 (es) |
| CA (1) | CA2977621C (es) |
| EA (1) | EA036490B1 (es) |
| MX (1) | MX388251B (es) |
| MY (1) | MY178445A (es) |
| WO (1) | WO2016137108A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072691A1 (en) † | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| SG10201502587SA (en) | 2010-03-01 | 2015-06-29 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| KR20230074843A (ko) | 2015-08-19 | 2023-05-31 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
| US20190096967A1 (en) * | 2017-09-25 | 2019-03-28 | Shenzhen China Star Optoelectronics Semiconductor Display Technology Co., Ltd. | Organic electroluminescent display apparatus |
| AU2019272184B2 (en) * | 2018-05-23 | 2022-01-27 | Mogam Institute For Biomedical Research | Antigen variant of varicella zoster virus and use thereof |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
| CN113440601B (zh) * | 2021-02-08 | 2022-01-21 | 中山大学 | Nk细胞和tfpi联用在防治鼻咽癌中的应用 |
| CN118715235A (zh) * | 2022-01-30 | 2024-09-27 | 西湖大学 | 预防和/或治疗由分支2菌株引起的艰难梭菌感染的组合物和方法 |
| CN117285632A (zh) * | 2022-06-17 | 2023-12-26 | 安源医药科技（上海）有限公司 | 针对tfpi的单克隆抗体及其用途 |
| CN117503911A (zh) * | 2023-12-08 | 2024-02-06 | 北京京佑奇康科技有限公司 | 治疗血友病的药物组合物及用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378614A (en) | 1989-08-18 | 1995-01-03 | Novo Nordisk A/S | Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast |
| US8036698B2 (en) * | 2005-01-14 | 2011-10-11 | Qualcomm Incorporated | Mobile station message having a station class mark field for indicating an MEID capable mobile station |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| CN104984319B (zh) * | 2008-12-19 | 2025-05-09 | 武田药品工业株式会社 | Tfpi抑制剂和使用方法 |
| EP2379599B1 (en) * | 2008-12-22 | 2015-09-02 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| SG10201502587SA (en) * | 2010-03-01 | 2015-06-29 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| ES2684475T3 (es) * | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| EP2588499B1 (en) * | 2010-06-30 | 2020-04-08 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| HUE042706T2 (hu) | 2011-04-01 | 2019-07-29 | Bayer Healthcare Llc | Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen |
| MX2014011781A (es) | 2012-03-30 | 2014-11-26 | Bayer Healthcare Llc | Anticuerpos regulados por proteasa. |
| RS56814B1 (sr) * | 2013-03-15 | 2018-04-30 | Bayer Healthcare Llc | Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike |
| US10457743B2 (en) * | 2013-07-19 | 2019-10-29 | Novo Nordisk A/S | Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| KR20150026555A (ko) | 2013-09-03 | 2015-03-11 | 한국터치스크린(주) | 터치패널의 본딩장치 및 이를 이용한 터치패널의 본딩방법 |
| KR101744899B1 (ko) | 2015-02-25 | 2017-06-08 | 재단법인 목암생명과학연구소 | 신규 항-tfpi 항체 및 이를 포함하는 조성물 |
-
2015
- 2015-12-29 EP EP15883495.2A patent/EP3262075B1/en active Active
- 2015-12-29 MY MYPI2017001261A patent/MY178445A/en unknown
- 2015-12-29 CN CN202010974386.1A patent/CN112225812B/zh active Active
- 2015-12-29 AU AU2015384281A patent/AU2015384281B2/en active Active
- 2015-12-29 WO PCT/KR2015/014370 patent/WO2016137108A1/en not_active Ceased
- 2015-12-29 CA CA2977621A patent/CA2977621C/en active Active
- 2015-12-29 JP JP2017545218A patent/JP6660957B2/ja active Active
- 2015-12-29 US US15/553,292 patent/US10266607B2/en active Active
- 2015-12-29 MX MX2017010763A patent/MX388251B/es unknown
- 2015-12-29 BR BR112017018328A patent/BR112017018328A2/pt not_active Application Discontinuation
- 2015-12-29 CN CN201580078235.5A patent/CN107428838B/zh active Active
- 2015-12-29 EP EP23196718.3A patent/EP4279128A3/en active Pending
- 2015-12-29 EA EA201791898A patent/EA036490B1/ru unknown
-
2019
- 2019-02-19 AU AU2019201141A patent/AU2019201141B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015384281A1 (en) | 2017-09-21 |
| CA2977621A1 (en) | 2016-09-01 |
| CN112225812A (zh) | 2021-01-15 |
| EP4279128A3 (en) | 2024-02-28 |
| AU2019201141B2 (en) | 2020-05-07 |
| MX388251B (es) | 2025-03-19 |
| EP3262075B1 (en) | 2024-03-13 |
| US10266607B2 (en) | 2019-04-23 |
| CN112225812B (zh) | 2024-08-13 |
| US20180030151A1 (en) | 2018-02-01 |
| JP2018511305A (ja) | 2018-04-26 |
| EP4279128A2 (en) | 2023-11-22 |
| EP3262075A1 (en) | 2018-01-03 |
| WO2016137108A1 (en) | 2016-09-01 |
| BR112017018328A2 (pt) | 2018-07-10 |
| CN107428838A (zh) | 2017-12-01 |
| EP3262075C0 (en) | 2024-03-13 |
| AU2015384281B2 (en) | 2018-11-22 |
| CA2977621C (en) | 2021-11-23 |
| CN107428838B (zh) | 2021-01-01 |
| AU2019201141A1 (en) | 2019-03-14 |
| EP3262075A4 (en) | 2018-08-08 |
| JP6660957B2 (ja) | 2020-03-11 |
| MY178445A (en) | 2020-10-13 |
| EA201791898A1 (ru) | 2018-03-30 |
| EA036490B1 (ru) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010763A (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| CO2018006590A2 (es) | Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1 | |
| MX2018003198A (es) | Moduladores de proteínas básicas de la hepatitis b. | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| MY209831A (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| MX384264B (es) | Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
| BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EA202092187A1 (ru) | Способы лечения эпителиоидно-клеточных опухолей | |
| MX2019005300A (es) | Polimeros enlazados al proton para administracion oral. | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). | |
| EA201791182A1 (ru) | Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |